Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Overcoming Challenges in AAV and LV Viral Vector Manufacturing | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

Overcoming Challenges in AAV and LV Viral Vector Manufacturing

How to design and launch a successful Clinical Trial Manufacturing.

Released By IDT Biologika

Cell and gene therapies are growing exponentially across the pharmaceutical field due to their potential to treat and possibly cure a wide range of devastating diseases, including cancer. As these therapies are becoming more wide spread, many drug sponsors are approaching trials with limited knowledge of how to design and launch a successful clinical trial manufacturing (CTM) process. This includes how to strategically investigate and manufacture adeno-associated virus vectors (AAVs) and lentiviral vectors (LVVs), two of the leading viral vectors used for gene therapeutics. Sponsors are faced with a stark learning curve that, without intervention, may lead to high costs, delays, and a failure to bring their drug to patients.

The key to avoiding process failures is leveraging innovative testing and manufacturing platforms that can reduce timelines and increase cost-savings for viral vector production. Collaborating with a contract development and manufacturing organization (CDMO) with AAV and LVV manufacturing expertise will help your team design a seamless and scalable process while also avoiding expensive mistakes.

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics